Goldman Sachs Maintains Neutral on Ionis Pharmaceuticals, Lowers Price Target to $41
Benzinga Newsdesk 54 minutes ago
Analyst RatingsNewsPrice Target
Goldman Sachs analyst Salveen Richter maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Neutral and lowers the price target from $58 to $41.
Goldman Sachs analyst Salveen Richter maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Neutral and lowers the price target from $58 to $41.